Compare VENUS REMEDIES with Orchid Chemicals - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VENUS REMEDIES vs ORCHID PHARMA LTD - Comparison Results

ORCHID PHARMA LTD 
   Change

Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) is today a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    VENUS REMEDIES ORCHID PHARMA LTD VENUS REMEDIES/
ORCHID PHARMA LTD
 
P/E (TTM) x -1.0 -0.5 - View Chart
P/BV x 0.1 0.1 60.4% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 VENUS REMEDIES   ORCHID PHARMA LTD
EQUITY SHARE DATA
    VENUS REMEDIES
Mar-18
ORCHID PHARMA LTD
Sep-13
VENUS REMEDIES/
ORCHID PHARMA LTD
5-Yr Chart
Click to enlarge
High Rs126194 64.9%   
Low Rs6135 174.6%   
Sales per share (Unadj.) Rs301.8276.5 109.2%  
Earnings per share (Unadj.) Rs-24.9-79.2 31.4%  
Cash flow per share (Unadj.) Rs2.5-43.5 -5.9%  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs293.353.9 543.7%  
Shares outstanding (eoy) m12.3470.45 17.5%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x0.30.4 74.8%   
Avg P/E ratio x-3.8-1.4 260.1%  
P/CF ratio (eoy) x36.7-2.6 -1,394.4%  
Price / Book Value ratio x0.32.1 15.0%  
Dividend payout %00-   
Avg Mkt Cap Rs m1,1548,067 14.3%   
No. of employees `0000.92.8 33.0%   
Total wages/salary Rs m3932,527 15.6%   
Avg. sales/employee Rs Th4,026.16,956.1 57.9%   
Avg. wages/employee Rs Th425.0902.5 47.1%   
Avg. net profit/employee Rs Th-331.8-1,993.0 16.6%   
INCOME DATA
Net Sales Rs m3,72419,477 19.1%  
Other income Rs m23407 5.5%   
Total revenues Rs m3,74719,884 18.8%   
Gross profit Rs m3951,103 35.8%  
Depreciation Rs m3382,519 13.4%   
Interest Rs m3545,227 6.8%   
Profit before tax Rs m-275-6,236 4.4%   
Minority Interest Rs m020 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0511 0.0%   
Tax Rs m32-125 -25.2%   
Profit after tax Rs m-307-5,580 5.5%  
Gross profit margin %10.65.7 187.3%  
Effective tax rate %-11.52.0 -571.7%   
Net profit margin %-8.2-28.7 28.8%  
BALANCE SHEET DATA
Current assets Rs m2,63811,014 23.9%   
Current liabilities Rs m2,30532,060 7.2%   
Net working cap to sales %8.9-108.1 -8.3%  
Current ratio x1.10.3 333.1%  
Inventory Days Days13595 142.7%  
Debtors Days Days4634 138.1%  
Net fixed assets Rs m4,87129,440 16.5%   
Share capital Rs m123705 17.5%   
"Free" reserves Rs m3,4962,043 171.1%   
Net worth Rs m3,6193,800 95.2%   
Long term debt Rs m1,3749,018 15.2%   
Total assets Rs m7,50946,510 16.1%  
Interest coverage x0.2-0.2 -115.5%   
Debt to equity ratio x0.42.4 16.0%  
Sales to assets ratio x0.50.4 118.4%   
Return on assets %0.6-0.8 -83.1%  
Return on equity %-8.5-146.9 5.8%  
Return on capital %1.6-3.7 -42.4%  
Exports to sales %037.9 0.0%   
Imports to sales %13.922.6 61.3%   
Exports (fob) Rs mNA7,378 0.0%   
Imports (cif) Rs m5174,406 11.7%   
Fx inflow Rs m07,513 0.0%   
Fx outflow Rs m5175,649 9.1%   
Net fx Rs m-5171,865 -27.7%   
CASH FLOW
From Operations Rs m5141,682 30.6%  
From Investments Rs m-123-9,860 1.2%  
From Financial Activity Rs m-3876,644 -5.8%  
Net Cashflow Rs m4-1,535 -0.3%  

Share Holding

Indian Promoters % 32.9 32.3 101.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.2 4.6 3.9%  
FIIs % 0.6 3.3 17.6%  
ADR/GDR % 0.0 4.6 -  
Free float % 66.4 55.3 120.1%  
Shareholders   20,121 84,811 23.7%  
Pledged promoter(s) holding % 36.4 54.9 66.2%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare VENUS REMEDIES With:   WYETH LTD  PIRAMAL ENTERPRISES  NATCO PHARMA  AUROBINDO PHARMA  PFIZER  

Compare VENUS REMEDIES With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Extend Gains; Tata Motors & ONGC Climb 5%(12:30 pm)

Share markets in India have extended early morning gains and are presently trading higher. Investors are cautious ahead of the release of Consumer Price Index-based inflation.

Related Views on News

VENUS REMEDIES Announces Quarterly Results (4QFY19); Net Profit Down 11.1% (Quarterly Result Update)

Jun 12, 2019 | Updated on Jun 12, 2019

For the quarter ended March 2019, VENUS REMEDIES has posted a net profit of Rs 104 m (down 11.1% YoY). Sales on the other hand came in at Rs 864 m (down 7.3% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

VENUS REMEDIES Announces Quarterly Results (3QFY19); Net Profit Down 2301.8% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, VENUS REMEDIES has posted a net profit of Rs 119 m (down 2301.8% YoY). Sales on the other hand came in at Rs 691 m (down 25.8% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

ORCHID PHARMA LTD Announces Quarterly Results (2QFY19); Net Profit Up 67.1% (Quarterly Result Update)

Jan 31, 2019 | Updated on Jan 31, 2019

For the quarter ended September 2018, ORCHID PHARMA LTD has posted a net profit of Rs 231 m (up 67.1% YoY). Sales on the other hand came in at Rs 1 bn (down 31.9% YoY). Read on for a complete analysis of ORCHID PHARMA LTD's quarterly results.

VENUS REMEDIES 2017-18 Annual Report Analysis (Annual Result Update)

Dec 21, 2018 | Updated on Dec 21, 2018

Here's an analysis of the annual report of VENUS REMEDIES for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of VENUS REMEDIES. Also includes updates on the valuation of VENUS REMEDIES.

VENUS REMEDIES Announces Quarterly Results (2QFY19); Net Profit Down 16.3% (Quarterly Result Update)

Nov 23, 2018 | Updated on Nov 23, 2018

For the quarter ended September 2018, VENUS REMEDIES has posted a net profit of Rs 8 m (down 16.3% YoY). Sales on the other hand came in at Rs 809 m (down 10.6% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

More Views on News

Most Popular

Finally, Is the Share Price of Yes Bank Ready for a Rebound?(The 5 Minute Wrapup)

Oct 7, 2019

Here's what every individual investor must know about Yes Bank...

What if Indiabulls Housing Finance and Yes Bank Do Not Rebound?(Profit Hunter)

Oct 1, 2019

How long should you wait for fallen blue chips like Yes Bank and Indiabulls Housing Finance to rebound?

Rebound Riches Could be Yours With These Stocks(Profit Hunter)

Oct 4, 2019

The secret to multibagger is not big businesses, but great managements... Here's how to find them to make the most of once in a decade rebound opportunity.

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

Foreign Money is Chasing Indian Stocks Once Again(The 5 Minute Wrapup)

Oct 4, 2019

Around Rs 75 billion poured into the Indian stock market in the month of September.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

VENUS REMEDIES SHARE PRICE


Oct 14, 2019 01:17 PM

TRACK VENUS REMEDIES

  • Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON VENUS REMEDIES

VENUS REMEDIES 8-QTR ANALYSIS

COMPARE VENUS REMEDIES WITH

MARKET STATS